The preeclampsia diagnostics market comprises products that enable early and effective diagnosis of preeclampsia during pregnancy. Preeclampsia is a pregnancy complication characterized by high blood pressure and signs of damage to other organ systems, mostly the liver and kidneys. It is one of the leading causes of maternal and infant illness and death globally if undetected. Preeclampsia diagnostics help identify at-risk pregnancies and provide timely intervention if symptoms arise. Common diagnostic tests used include blood and urine tests to detect protein in urine samples, monitor blood pressure levels, and check blood cell count and liver and kidney functions. Fetal ultrasounds are also done to check fetal growth and development. The accessibility of reliable diagnostic tools enables early risk identification and management, improving health outcomes for both mother and baby.

The global Preeclampsia Diagnostics Market is estimated to be valued at Us$ 1587.53 Mn in 2023 and is expected to exhibit a CAGR Of 5.6% over the forecast period 2023 To 2030, as highlighted in a new report published by Coherent Market Insights.

Market key trends:

One of the major trends in the preeclampsia diagnostics market is the increased adoption of portable monitoring devices. Management of high-risk pregnancies requires frequent monitoring of vital health parameters like blood pressure. The availability of portable blood pressure monitors and fetal heart rate monitors has greatly benefited at-risk mothers and healthcare providers. It allows continuous monitoring even from home, alerting early signs for timely intervention. Ongoing research is also evaluating novel biomarkers to enable early-stage diagnosis even before clinical symptoms appear. Identification of biomarkers indicative of placental dysfunction could revolutionize preeclampsia screening. Development of rapid diagnostic tests leveraging biomarker detection also promises improved access in resource-limited areas. These ongoing innovations are expected to further increase market penetration over the forecast period.

Porter’s Analysis:

Threat of new entrants: The threat of new entrants in the preeclampsia diagnostics market is low as it requires huge R&D investments and regulatory approvals. The established key players also have scale advantages.

Bargaining power of buyers: The bargaining power of buyers in the preeclampsia diagnostics market is moderate. The existence of many diagnostic test manufacturers limits the buyer leverage to an extent.

Bargaining power of suppliers: The bargaining power of suppliers is moderate due to the availability of substitute raw materials and components. However, suppliers may bargain over prices of key diagnostic components.

Threat of new substitutes: The threat of new substitutes is low as diagnostic tests and equipment for preeclampsia have limitations and preeclampsia symptom management requires customized care.

Competitive rivalry: The competitive rivalry in the market is high owing to the presence of numerous global and regional players offering varied diagnostic products. Players compete based on product pricing and delivery.

Key Takeaways

The Global Preeclampsia Diagnostics Market Demand is expected to witness high growth due to the rising incidence of preeclampsia among expectant mothers. The global preeclampsia diagnostics market is estimated to be valued at US$ 1587.53 Mn in 2023 and is expected to exhibit a CAGR of 5.6% over the forecast period 2023 to 2030.

Regional analysis :

North America is expected to dominate the global market during the forecast period due to increasing awareness about preeclampsia diagnosis and favourable reimbursement policies in the region. However, Asia Pacific is likely to witness the highest growth rate owing to improving healthcare infrastructure and growing medical tourism in the region.

Key players :

Key players operating in the preeclampsia diagnostics market are AstraZeneca, CorMedix, Inc., Citius Pharmaceuticals, Fresenius Medical Care, Glenmark Pharmaceuticals Ltd., Geistlich Pharma, Merck & Co., Inc., Pfizer, TauroPhar GmbH, and Xellia Pharmaceuticals Ltd. Fresenius Medical Care and Merck & Co., Inc. collectively hold a significant share of the market.

Note:
1. Source: Coherent Market Insights, Public sources, Desk research
2. We have leveraged AI tools to mine information and compile it